Through this agreement, Artes Medical’s dedicated sales force will market and sell Elevess, the first FDA-approved HA dermal filler for the temporary correction of facial wrinkles that is formulated with an anesthetic for patient comfort, as well as the company’s flagship product, ArteFill, the first and only FDA-approved non-resorbable wrinkle filler for long-lasting correction of smile line wrinkles. As a result, Artes Medical becomes the first and only company in the U.S. with a product portfolio of approved dermal fillers that provide patients with a full range of treatment options.
Under the terms of the agreement, Anika Therapeutics will manufacture Elevess and supply Artes Medical with a fully packaged product. Artes Medical will be responsible for the marketing and sale of Elevess to dermatologists, plastic surgeons and cosmetic surgeons in the U.S.
About Elevess
Anika’s Elevess is the first FDA approved injectable soft-tissue filler to combine hyaluronic acid (HA) and lidocaine, a local anesthetic that improves patient comfort, and provides physicians with a new alternative for their aesthetic practice. Hyaluronic acid is a naturally occurring polymer found throughout the body and is present in the skin, where it supports skin structure and elasticity. Designed for longer durability based on its proprietary cross-linking technology and its high concentration of Anika’s chemically modified hyaluronic acid, Elevess has been approved for sale in the United States, the European Union and Canada.
Tidak ada komentar:
Posting Komentar